Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Purchased by Ally Bridge Group NY LLC

Ally Bridge Group NY LLC boosted its holdings in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 2.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 270,075 shares of the company’s stock after acquiring an additional 5,415 shares during the quarter. Tyra Biosciences comprises 3.4% of Ally Bridge Group NY LLC’s holdings, making the stock its 12th largest holding. Ally Bridge Group NY LLC owned approximately 0.53% of Tyra Biosciences worth $6,349,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its position in Tyra Biosciences by 12.3% in the second quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after buying an additional 2,574 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Tyra Biosciences by 2.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 173,737 shares of the company’s stock valued at $4,085,000 after purchasing an additional 3,792 shares during the last quarter. Oppenheimer & Co. Inc. raised its position in Tyra Biosciences by 9.0% in the third quarter. Oppenheimer & Co. Inc. now owns 76,806 shares of the company’s stock valued at $1,806,000 after purchasing an additional 6,318 shares during the period. Jennison Associates LLC lifted its stake in Tyra Biosciences by 5.9% during the third quarter. Jennison Associates LLC now owns 158,187 shares of the company’s stock worth $3,719,000 after purchasing an additional 8,837 shares in the last quarter. Finally, Valence8 US LP purchased a new position in shares of Tyra Biosciences during the third quarter worth $310,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on TYRA. Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $22.00 to $31.00 in a report on Friday, October 18th. Oppenheimer lifted their target price on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research report on Thursday, September 19th. HC Wainwright reduced their price target on shares of Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. Piper Sandler initiated coverage on shares of Tyra Biosciences in a report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price objective for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a research note on Friday, October 25th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Tyra Biosciences presently has an average rating of “Buy” and a consensus price target of $31.00.

Tyra Biosciences Price Performance

TYRA stock opened at $16.00 on Thursday. Tyra Biosciences, Inc. has a 1 year low of $10.60 and a 1 year high of $29.60. The firm has a market capitalization of $809.60 million, a P/E ratio of -9.94 and a beta of 1.08. The business’s 50-day moving average is $20.43 and its two-hundred day moving average is $19.85.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). On average, analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Insider Buying and Selling

In related news, Director Nina S. Kjellson sold 27,493 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $16.56, for a total transaction of $455,284.08. Following the completion of the sale, the director now owns 458,506 shares in the company, valued at $7,592,859.36. The trade was a 5.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Alan Fuhrman purchased 9,500 shares of the stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average cost of $16.00 per share, with a total value of $152,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 12,849 shares of the company’s stock, valued at $205,584. This represents a 283.67 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 101,050 shares of company stock worth $2,235,492. Corporate insiders own 15.40% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.